Rhythm Pharma Q2 Revenue Hits $71.3M, IMCIVREE Launch Surges with 400 Patient Start Forms
RYTM sits 41% above its 52-week low of $74.5.
Summary
Rhythm Pharmaceuticals reported Q2 2026 net product revenue of $71.3 million, a 19% sequential increase driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). More than 400 patient start forms were received from approximately 300 prescribers as of June 30, 2026, signaling strong early demand. U.S. revenue jumped 38% sequentially to $51.0 million, while ex-U.S. revenue dipped to $20.3 million due to a one-time French pricing charge. The company's net loss narrowed, reflecting the strong U.S. launch demand. Clinically, weekly injectable RM-718 showed a mean BMI reduction of 11.6% in acquired HO patients after 16 weeks, and Phase 3 TRANSCEND results were published in the New England Journal of Medicine. This follows positive Phase 2 data in Prader-Willi syndrome and broader MC4R agonist data presented at ENDO 2026 in June.
At the time of this announcement, RYTM was trading at $105.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.